A new wave of prescription drugs is breaking ground by helping patients drop unwanted pounds, address Type-2 diabetes, reduce the risk of deadly heart problems, and possibly even help battle alcoholism.
A small study of only six people who screened positive for alcohol use disorder showed a significant decrease in symptoms while using semaglutide, the active ingredient in the popular drugs Ozempic and Wegovy. The study will likely lead to a larger, more reliable one.
Doctors view Ozempic and Wegovy as well as similar drugs Mounjaro and Zepbound as game changers. Studies show these drugs can help users lose an average of between five and twenty percent of their body weight, even if patients have tried unsuccessfully to lose weight in the past.
***Please sign up for CBN Newsletters and download the CBN News app to ensure you keep receiving the latest news.***
All four drugs target the body’s hormones to increase the feeling of fullness, decrease hunger, and slow the G-I tract. They’re FDA-approved to treat Type-2 diabetes, obesity, or both. The company Novo Nordisk makes Ozempic and Wegovy, which contain the active ingredient semaglutide, which targets one hormone.
The drug company Eli Lilly manufactures Mounjaro and Zepbound, which contain the
The remainder of this article is available in its entirety at CBN